Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel Geoffrey Tenen, M.D.

Co-Author

This page shows the publications co-authored by Daniel Tenen and Susumu Kobayashi.
Connection Strength

2.219
  1. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 10 14; 138(15):1331-1344.
    View in: PubMed
    Score: 0.241
  2. Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation. Bioorg Med Chem Lett. 2019 08 15; 29(16):2286-2289.
    View in: PubMed
    Score: 0.205
  3. Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPa. Molecules. 2018 Aug 03; 23(8).
    View in: PubMed
    Score: 0.193
  4. ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPa. J Biol Chem. 2017 11 17; 292(46):18924-18936.
    View in: PubMed
    Score: 0.182
  5. A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen. 2015 Oct; 20(9):1150-9.
    View in: PubMed
    Score: 0.156
  6. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010 Jul; 137(13):2147-56.
    View in: PubMed
    Score: 0.110
  7. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010 Apr 08; 115(14):2901-9.
    View in: PubMed
    Score: 0.107
  8. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
    View in: PubMed
    Score: 0.098
  9. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008 Mar 01; 26(7):1182-4; author reply 1184-6.
    View in: PubMed
    Score: 0.094
  10. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
    View in: PubMed
    Score: 0.091
  11. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep; 117(9):2611-20.
    View in: PubMed
    Score: 0.091
  12. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705.
    View in: PubMed
    Score: 0.090
  13. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98.
    View in: PubMed
    Score: 0.086
  14. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6338-43.
    View in: PubMed
    Score: 0.082
  15. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101.
    View in: PubMed
    Score: 0.079
  16. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
    View in: PubMed
    Score: 0.076
  17. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7.
    View in: PubMed
    Score: 0.031
  18. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
    View in: PubMed
    Score: 0.028
  19. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94.
    View in: PubMed
    Score: 0.025
  20. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38.
    View in: PubMed
    Score: 0.024
  21. Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J Biol Chem. 2008 Jun 27; 283(26):18002-11.
    View in: PubMed
    Score: 0.024
  22. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 01; 67(21):10417-27.
    View in: PubMed
    Score: 0.023
  23. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
    View in: PubMed
    Score: 0.022
  24. Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magn Reson Med. 2006 Sep; 56(3):698-703.
    View in: PubMed
    Score: 0.021
  25. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95.
    View in: PubMed
    Score: 0.021
  26. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.